Compare BioNano Genomics Inc (BNGO) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Procter & Gamble Co — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.31M), while Procter & Gamble Co trades at $144.61 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 25574× BioNano Genomics Inc's market cap, and Procter & Gamble Co pays a 2.97% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PG | |
|---|---|---|
Market Cap | $13.31M | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $167.18 |
52-Week Low | $1.06 | $138.10 |
Enterprise Value | $15.92M | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16, up 5.45% today, with a bullish technical signal from moving averages. The company shows improving financial trends with revenue stabilizing around $29M annually and narrowing losses from -$232M in 2023 to -$26M in 2025. Recent earnings beats and positive news flow around optical genome mapping adoption support momentum.
While BNGO demonstrates operational improvement and analyst support (57% buy ratings), the stock faces significant risks including persistent negative profitability, cash burn requiring ongoing financing, and competitive pressures in genomic technology. The current valuation appears attractive on P/S and P/B metrics but reflects the company's pre-profitability stage.
Procter & Gamble (PG) trades at $146.38, up 0.42% on the day, with a bearish technical signal but strong fundamentals including a net income margin of 18.44% and consistent earnings beats. The company maintains robust cash flow from operations of $17.82B in 2025 and a dividend track record, with a recent partnership with the WNBA signaling strategic brand expansion. Valuation ratios like P/E of 22.12 and P/S of 4.08 reflect a premium to peers amid modest revenue growth.
PG offers stability with high profitability and dividend reliability, but premium valuation and soft demand outlook pose near-term risks. Analyst consensus is bullish with a $161.20 price target, though technical indicators suggest caution. Key risks include economic sensitivity and competitive pressures, while institutional holdings show mixed sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
